No Homerun, But A Base Hit For Teva's Laquinimod
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva's Phase III ALLEGRO study shows the once-daily oral multiple sclerosis candidate still has promise, but efficacy data underwhelms.
You may also be interested in...
Teva Faces Laquinimod Setback After High Dose Linked To CV Events
Teva will discontinue higher doses of laqunimod in two ongoing studies for multiple sclerosis after cardiovascular events were experienced in eight patients. Trials will continue with a lower dose.
Teva Pins Long-Term Hopes In MS On The Return Of Laquinimod
Teva has ambitions to file in 2018 after the Phase III CONCERTO trial reads out in 2017. Firm is studying a higher dose of the drug and relying on a different primary endpoint, hoping to show stronger efficacy over a Phase III trial that failed in 2011.
Third Trial For Teva’s Laquinimod Hinges On SPA From FDA
Teva will initiate a third clinical trial testing the oral multiple sclerosis drug laquinimod after finalizing a special protocol assessment with FDA.